. . . . . . "drugbank_resource:DB00258_DB01212" . "DDI between Calcium Acetate and Ceftriaxone - Calcium Salts (Intravenous) may enhance the adverse/toxic effect of Ceftriaxone. Ceftriaxone binds to calcium forming an insoluble precipitate. Concurrent or sequential use (within 48 hours) of ceftriaxone with calcium-containing solutions is contraindicated in neonates (28 days of age or younger). In other patients, these solutions can be used sequentially if the infusion lines are flushed with a compatible fluid between ceftriaxone and calcium-containing solution infusion."@en . . "DDI between Calcium Acetate and Ceftriaxone - Calcium Salts (Intravenous) may enhance the adverse/toxic effect of Ceftriaxone. Ceftriaxone binds to calcium forming an insoluble precipitate. Concurrent or sequential use (within 48 hours) of ceftriaxone with calcium-containing solutions is contraindicated in neonates (28 days of age or younger). In other patients, these solutions can be used sequentially if the infusion lines are flushed with a compatible fluid between ceftriaxone and calcium-containing solution infusion. [drugbank_resource:DB00258_DB01212]"@en . . "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" . "MCwCFCDCW5D4A87dWXfOpwSvU37JODTgAhQ5wSQtb1Xh88Yeds5bHrKGxd6sqA==" . . "2018-03-30T11:12:39.122+02:00"^^ . . . . . . "3c184e6c-ceb8-4275-a679-71dfbdac2a11" . . . . . "eda7951a5f6c622c5d2132f50c3093138484a349" . .